AIDS 2026 Day 4 on Thursday July 30 in Rio de Janeiro Continues With Lenacapavir Implementation Science Programming Including a Cross-Country Implementation Learning Presentation Introducing a Structured Demand Generation Playbook Supporting Effective Introduction and Uptake of Lenacapavir Within a Broader PrEP Choice Framework (16:33-16:41 BRT / 3:33-3:41 PM EDT), Plus the ANRS RHIVIERA Consortium Satellite Symposium 6:00-7:30 PM BRT on 'Treatment Interruption and Treatment Resumption: Lessons Learned From HIV Cure Clinical Trials'
The 26th International AIDS Conference (AIDS 2026) Day 4 continued Thursday July 30, 2026 at Riocentro in Rio de Janeiro. Two Thursday programming highlights: a cross-country implementation learning presentation on lenacapavir demand generation (16:33-16:41 BRT / 3:33-3:41 PM EDT) that introduces a structured demand generation playbook supporting effective introduction and uptake of lenacapavir within a broader PrEP Choice framework, following the Wednesday late-breaker on the Gilead-Merck ISLEND-1 and ISLEND-2 detailed Phase 3 data and the 52-week PURPOSE 1 and PURPOSE 2 open-label extension data on twice-yearly injectable lenacapavir. The ANRS RHIVIERA consortium (French research agency) satellite symposium (18:00-19:30 BRT) covers 'Treatment interruption and treatment resumption: lessons learned from HIV cure clinical trials,' addressing the analytical treatment interruption (ATI) research methodology and the observational learnings from HIV cure-focused trials that have paused antiretroviral therapy to test cure candidates. The conference closes Friday July 31 with the closing session and additional late-breaker presentations. Generic lenacapavir from Dr. Reddy's Laboratories, Hetero Labs, and four other manufacturers is expected in 2027 at approximately $40 per person per year across 120 low- and lower-middle-income countries.